

Preliminary Agenda

healthbook CME Live Webinar

Secondary Immunodeficiency (SID) in the Era of Cellular and Immune Therapies

From Risk Assessment to Personalized Infection Prevention

Organisation:	H+O communications Ltd. and healthbook
Date:	Thursday, December 10, 2026
Duration:	18:00 – 19:50, 110 min
Target groups:	Hemato-Oncologists; Medical Oncologists, Infectious Disease Specialists and Clinical Immunologists
Language:	English
Sponsors:	Gilead Kite and further co-sponsors

Objectives:

- Understand how modern immune therapies reshape the risk of secondary immunodeficiency
- Improve identification of patients at highest infection risk
- Discuss practical monitoring strategies before, during and after CAR-T and other B-cell-depleting therapies
- Review current evidence for immunoglobulin replacement and infection prevention
- Learn from multidisciplinary real-world cases

Preliminary Agenda

18:00 – 18:05	Welcome and Introduction Co-Chairs: Prof. Frank Stenner (USB Basel) and Prof. Mike Recher (USB Basel) Opening: Dr Ellen Heitlinger, healthbook	5'
18:05 – 18:30	Secondary Immunodeficiency in 2026 Which Patients are Truly at Highest Risks? Topics: • Evolving SID landscape • Biomarkers • Guideline Updates • Patient Stratification Prof. Mike Recher (USB Basel)	<i>Presentation & Discussion time: 20'+5'</i>
18:30 – 18:55	CAR-T Therapy: Beyond Cytokines – Long-term Immune Reconstitution and Infection Prevention Topics: • YESCARTA • Long-term B-cell aplasia • Hypogammaglobulinemia • Vaccination • Follow-up Dr Dr Marc Wehrli (University Hospital Inselspital Bern)	<i>Presentation & Discussion time: 20'+5'</i>
18:55 – 19:20	Personalized Immunoglobulin Replacement Therapy Which patient? Which timing? Which route? Topics: • IVIg vs SCIg • Guideline Implementation • Individualized Treatment • Monitoring Response Prof. Frank Stenner (USB Basel)	<i>Presentation & Discussion time: 20'+5'</i>
19:20 – 19:45	Multidisciplinary Patient Conference Real-world SID Management in Patients receiving CAR-T, Bispecific Antibodies and other B-cell-targeted Therapies Dr Guido Ghilardi A Hematologist, an Immunologist and an Infectious Disease Specialist	<i>Presentation & Discussion time: 25'</i>
19:45 – 19:50	Conclusions Co-Chairs: Prof. Frank Stenner (USB Basel) and Prof. Mike Recher (USB Basel) Closing: Dr Ellen Heitlinger, healthbook	5'